Technical Analysis for ACRX - AcelRx Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 2.74 -2.14% -0.06
ACRX closed down 2.14 percent on Friday, May 24, 2019, on 53 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical ACRX trend table...

Date Alert Name Type % Chg
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Wide Bands Range Expansion -2.14%
Oversold Stochastic Weakness -2.14%
Wide Bands Range Expansion -5.52%
Oversold Stochastic Weakness -5.52%
Wide Bands Range Expansion -7.43%
Oversold Stochastic Weakness -7.43%
New Downtrend Bearish -4.20%

Older signals for ACRX ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

AcelRx Pharmaceuticals, Inc., a development stage specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute and breakthrough pain. The company's principal product candidate is ARX-01, a Sufentanil NanoTab PCA system, which is in Phase III clinical trials for acute post-operative pain in patients in the hospital setting. Its product candidates also comprise ARX-02, a Sufentanil NanoTab BTP management system that has completed a Phase II clinical trial for the treatment of cancer patients who suffer from breakthrough pain; and ARX-03, a Sufentanil/Triazolam NanoTab, which has completed a Phase II clinical trial to provide mild sedation, anxiety reduction, and pain relief for patients undergoing painful procedures in a physician's office. In addition, the company's product candidate under development includes ARX-04, a Sufentanil Single-Dose NanoTab for the treatment of patients with moderate-to-severe acute pain either on the battlefield or in civilian settings of trauma or injury. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.
Chemistry Cancer Pain Chemical Compounds Organic Compounds Treatment Of Cancer Clinical Trial Injury Ethers Piperidines Fentanyl Stage Specialty Pharmaceutical Breakthrough Pain Sufentanil Thiophenes
Is ACRX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 5.05
52 Week Low 1.99
Average Volume 1,703,988
200-Day Moving Average 3.2134
50-Day Moving Average 3.345
20-Day Moving Average 3.2645
10-Day Moving Average 2.939
Average True Range 0.1893
ADX 28.69
+DI 12.4255
-DI 30.6996
Chandelier Exit (Long, 3 ATRs ) 3.4321
Chandelier Exit (Short, 3 ATRs ) 3.2679
Upper Bollinger Band 4.0138
Lower Bollinger Band 2.5152
Percent B (%b) 0.15
BandWidth 45.905958
MACD Line -0.1828
MACD Signal Line -0.1222
MACD Histogram -0.0606
Fundamentals Value
Market Cap 124.34 Million
Num Shares 45.4 Million
EPS -1.10
Price-to-Earnings (P/E) Ratio -2.49
Price-to-Sales 5.25
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.98
Resistance 3 (R3) 2.99 2.93 2.94
Resistance 2 (R2) 2.93 2.87 2.92 2.93
Resistance 1 (R1) 2.83 2.83 2.80 2.82 2.91
Pivot Point 2.77 2.77 2.75 2.76 2.77
Support 1 (S1) 2.67 2.71 2.64 2.66 2.57
Support 2 (S2) 2.61 2.67 2.60 2.55
Support 3 (S3) 2.51 2.61 2.54
Support 4 (S4) 2.50